



## Press Release

### Cenix BioScience signs research service agreement with Bayer Pharma AG

**Dresden, Germany, May 5, 2014** – Cenix BioScience GmbH (Cenix), a leading preclinical contract research provider and technology developer specialized in RNAi-based genomics and high content screening-driven pharmacology, today announced that it has signed a research service agreement with Bayer Pharma AG (Bayer).

Under the agreement, Cenix will undertake a target discovery project for an undisclosed disease indication by applying its longstanding industry-leading expertise in high throughput RNAi for genome-scale screening in advanced cell models.

Financial terms were not disclosed.

#### About Cenix BioScience

With operations in Germany and the U.S., Cenix BioScience conducts contract research and develops new reagent technologies focused on a wide array of preclinical cell-based and *in vivo* applications including RNAi-based gene silencing, miRNA modulation, compound testing, advanced genomics analyses and high content screening to accelerate drug discovery and development. Now in its 15<sup>th</sup> year, Cenix has established unrivaled scientific and commercial track records in this field, successfully advancing therapeutic programs for numerous industry and academic partners in a broad range of disease fields. This success, illustrated by a high rate of repeat business from top clients, is driven by the consistent application of industrial best practices through highly customized, multi-staged projects carefully designed for maximal strategic value and accountability, with minimized risk and full data transparency. More information: [www.cenix.com](http://www.cenix.com)

#### Contact

Dr. Christoph Sachse  
Director Cell-based Services  
E: [info@cenix.com](mailto:info@cenix.com)  
W: [www.cenix.com](http://www.cenix.com)

*Cenix and the Cenix BioScience logo are registered trademarks owned by Cenix BioScience GmbH.*